Baszczuk Aleksandra, Kopczyński Zygmunt, Kopczyński Jarosław, Cymerys Maciej, Thielemann Anna, Bielawska Lena, Banaszewska Anna
Department of Laboratory Diagnostics, Poznan University of Medical Sciences, Poland.
Department of Internal Medicine, Metabolic Disorders and Hypertension, Poznan University of Medical Sciences, Poland.
Postepy Hig Med Dosw (Online). 2015 Apr 7;69:429-35. doi: 10.5604/17322693.1148336.
The results of epidemiological and clinical tests have shown that in patients with primary arterial hypertension, a chronic mild inflammation develops. The purpose of the study was to determine whether administration of folic acid to patients with primary arterial hypertension influences concentrations of indicators of inflammation: hsCRP, sICAM-1 and sVCAM-1.
The examination was carried out in 41 patients with primary arterial hypertension, aged 19-65 (21 men and 20 women), without complications of hypertension and/or coexisting diseases. The examined patients were administered 15 mg of folic acid once a day for 45 days. Before and after administration of folic acid, concentrations of folic acid, homocysteine, hsCRP, sICAM-1 and sVCAM-1 in serum were assessed. Concentrations of folic acid and homocysteine were determined using the immunoenzymatic method (Abbott) on an AxSYM analyzer. The level of C-reactive protein (CRP) was determined with an ultra-sensitive turbidimetric assay on a Dimension analyzer (Siemens). Next, concentrations of adhesion particles sICAM-1 and sVCAM-1 were assessed with the ELISA technique (R&D).
After the administration of folic acid in patients with primary arterial hypertension, a significant decrease in median concentrations of homocysteine in blood was observed. Simultaneously, the median hsCRP, ICAM-1 and VCAM-1 concentrations in serum in patients with primary arterial hypertension were significantly reduced.
Administration of folic acid to persons with primary arterial hypertension in a dose of 15 mg/ day for 45 days caused a decrease in the concentration of homocysteine in serum. That could indirectly result in the decrease in concentrations of the indicators of inflammation (hsCRP, ICAM-1 and VCAM-1), as it is apparent from previous studies that hyperhomocysteinemia stimulates the synthesis of CRP and the expression of adhesion molecules.
流行病学和临床测试结果表明,原发性高血压患者会出现慢性轻度炎症。本研究的目的是确定对原发性高血压患者施用叶酸是否会影响炎症指标的浓度:高敏C反应蛋白(hsCRP)、可溶性细胞间黏附分子-1(sICAM-1)和可溶性血管细胞黏附分子-1(sVCAM-1)。
对41例年龄在19 - 65岁之间(21例男性和20例女性)的原发性高血压患者进行检查,这些患者无高血压并发症和/或并存疾病。对受检患者每天服用15毫克叶酸,持续45天。在服用叶酸前后,评估血清中叶酸、同型半胱氨酸、hsCRP、sICAM-1和sVCAM-1的浓度。使用免疫酶法(雅培)在AxSYM分析仪上测定叶酸和同型半胱氨酸的浓度。用Dimension分析仪(西门子)上的超敏比浊法测定C反应蛋白(CRP)水平。接下来,用酶联免疫吸附测定技术(R&D)评估黏附颗粒sICAM-1和sVCAM-1的浓度。
对原发性高血压患者施用叶酸后,观察到血液中同型半胱氨酸的中位数浓度显著降低。同时,原发性高血压患者血清中的hsCRP、ICAM-1和VCAM-1中位数浓度显著降低。
对原发性高血压患者每天服用15毫克叶酸,持续45天,可导致血清中同型半胱氨酸浓度降低。这可能间接导致炎症指标(hsCRP、ICAM-1和VCAM-1)浓度降低,因为先前的研究表明高同型半胱氨酸血症会刺激CRP的合成和黏附分子的表达。